Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, ...

Learn more about whether Recursion Pharmaceuticals, Inc. or Syndax Pharmaceuticals, Inc. is a better investment based on AAII ...

In late June 2026, Recursion Pharmaceuticals, Inc. was added to multiple Russell value and small-cap benchmarks, including ...

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...

In this piece we will look at the 5 Best Penny Stocks to Invest In According to Billionaires. Please visit 12 Best Penny ...

Two stocks that have fallen out of favor and one hot stock that was one of Thursday's biggest losers were on the Ark Invest ...

That admission is what some in the field call recursive self-improvement (RSI), the point at which large language models ...

While many AIs used to assist drug discovery are provided by big tech companies at a cost, a small US and China-based techbio ...

These aren't for the faint of heart.

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...

An updated edition of the May 18, 2026, article. The global oncology market is evolving rapidly, fueled by rising cancer incidence, an aging population and continued scientific innovation. According ...

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and ...